COVID-19 mRNA VACCINE SCREENING CHECKLIST

This resource is intended to assist healthcare providers while conducting an informed consent conversation and health assessment with a client. Questions listed below are related to the contraindications, precautions and special considerations for COVID-19 mRNA immunization, for which additional information can be found in the Yukon Immunization Manual – Section 8 – Biological Products.

CONTRAINDICATIONS: **A condition in a recipient that increases the risk for a serious adverse event. In general, a vaccine should not be administered when a contraindication is present.**	
1. Is the client under the age of 6 months?[1]	☐ No ☐ Yes If yes, **DO NOT VACCINATE**
2. Do you have any allergies to a vaccine component? *(Reference vaccine component table below)*	☐ No ☐ Yes If yes, **consult health care provider on which vaccine is most appropriate**
2b. If yes to #2, have you had anaphylaxis or severe allergy from an <u>unknown</u> cause?	☐ No ☐ Yes If yes, consider referral to specialist prior to immunization
3. Did you have any side effects after your last dose of COVID-19 vaccine?[2]	☐ No ☐ Yes If yes, and **reportable AEFI, DEFER**
PRECAUTIONS: **A condition in a recipient that might increase the risk for a serious adverse reaction or might compromise the ability of the vaccine to produce immunity. When a precaution is present, further assessment and a risk-benefit analysis may be necessary.**	
4. Do you have any problems with your immune system, or are you taking any medications that	☐ No ☐ Yes If yes, please provide client education AND **determine need for 3rd dose** (see 'COVID-19 Vaccine

[1] **If client answers 'yes' to question 1** DO NOT VACCINATE.
In the Yukon, Moderna SPIKEVAX XBB.1.5 (blue cap) presentation is used for individuals aged 6 months and older. Pfizer XBB.1.5 vaccine products are available for those with contraindications to receiving Moderna Spikevax formulations. Refer to Immunization Manual for product specific recommendations.

[2] **If client answers 'yes' to question 3:** and the AEFI is reportable, DEFER and submit an Adverse Events Following Immunization report in Panorama. Refer to the AEFI flow sheet for your facility or Section 13 of the Immunization Manual to determine if event is reportable.

Last updated: October 18, 2023

may affect your immune system? E.g. high dose steroids, chemotherapy[3]	Eligibility Chart' in section 8 of the manual)
5. Have you received monoclonal antibodies or convalescent plasma within the last 3 months?[4]	☐ No ☐ Yes If yes, **DEFER**
6. Have you been diagnosed with Multisystem Inflammatory Syndrome in Children (MIS-C) or Adults (MIS-A) within the last 3 months?[5]	☐ No ☐ Yes If yes, **DEFER**
7. Have you had COVID-19 infection in the last 6 months? [6]	☐ No ☐ Yes If yes, **MAY consider deferral**
SPECIAL CONSIDERATIONS:	
8. Are you feeling ill today?[7]	☐ No ☐ Yes If yes, **consider deferral**
9. Have you ever felt faint or fainted after a past vaccination or medical procedure?	☐ No ☐ Yes If yes, consider lying down

[3] **If client answers 'yes' to question 4:** mRNA COVID-19 vaccine series should be offered to individuals in the authorized age group who are immunosuppressed due to disease or treatment. Clients should be informed that they may have a reduced immune response and may require additional doses.

[4] **If client answers 'yes' to question 5**: Consult the client's primary physician and Yukon Immunization Program for guidance on how to proceed.

[5] **If client answers 'yes' to question 6**: DEFER vaccination for at least 90 days following date of MIS-C or MIS-A diagnosis and until they have recovered from illness.

[6] **If client answers 'yes' to question 7:** The CMOH recommends that the general population may receive a dose of COVID-19 vaccine at least 6 months after COVID-19 infection symptom onset. However, these individuals may make an informed decision to get vaccinated post-infection irrespective of this interval if it has been at least 2 weeks since the resolution of acute symptoms and minimum intervals are maintained. Residents of long-term care who experienced COVID-19 infection may receive a dose at least 2 weeks after COVID-19 resolution of acute symptoms to maximize their immunity over the fall respiratory season.

[7] **If the client answers 'yes' to question 8:** Determine if client has COVID-19 symptoms. If yes, DEFER, re-direct them to get COVID-19 testing and do not vaccinate.

Vaccine Components

COVID-19 mRNA Vaccine (Spikevax®) XBB.1.5 Royal blue cap; Coral blue label border	**Potential allergens:** PEG2000-DMG (1,2-dimyristoyl-rac-glycerol, methoxypolyethyleneglycol) **Other components:** acetic acid, cholesterol, DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), lipid SM-102, sodium acetate trihydrate, sucrose, trometamol, trometamol hydrochloride, water for injection.
COVID-19 mRNA Vaccine (Comirnaty®) XBB.1.5 Grey Cap; Grey Label Border	**Potential allergens**: 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide **Other components:** ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), cholesterol, DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), sodium chloride, sucrose, tromethamine, tromethamine hydrochloride, water for injection

FAQs for Immunocompromised Individuals

Why do immunocompromised clients require an additional dose?

The general population develops a robust immune response to COVID-19 vaccines, however immunocompromised individuals have a weakened immune system due to disease or treatment. These individuals are shown to have a lower immune response to COVID-19 vaccines compared to the general public. Recent studies show that some individuals who are moderately to severely immunocompromised who did not respond/had a reduced immune response after 2 doses of mRNA vaccine can have an increased response after a 3rd dose; this also aligns with contributing to health equity in the territory.

What is the dosing schedule for these clients?

These individuals should receive at least 3 doses of COVID-19 vaccine according to the intervals outlined in Section 8 of the Yukon Immunization Manual.

Will other immunocompromised clients not on this list require an additional dose to complete their series?

Based on the most recent scientific studies, NACI does not recommend that clients outside of the list outlined in section 8 of the manual require an additional dose.

Are there any safety concerns associated with administering an additional dose?

No safety concerns were identified in the scientific studies that NACI reviewed. Ongoing monitoring at both the territorial and national level will continue.

Last updated: October 18, 2023